Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.

Slides:



Advertisements
Similar presentations
TREATMENT DATA INDICATORS IN THE UNODC DATA COLLECTION SYSTEM.
Advertisements

NICE Guidance on Needle and Syringe Programmes: Providing Injecting Equipment to People who Inject Drugs. Professor Mike Kelly, PhD, FFPH. Director, The.
Needle exchange: an NTA perspective 1 July 2009 Hugo Luck.
For primary and secondary care settings
Needle and syringe programmes Implementing NICE guidance 2009 NICE public health guidance 18.
STREET OUTREACH. GOALS OF COURSE Identify who and what we are looking for. To identify techniques that can help in development of effective outreach.
Responses to infectious diseases among people who inject drugs: Policies and measures taken in Europe Dagmar Hedrich, EMCDDA Project Imp.Ac:T - Improving.
Children and young people, injecting and HIV Under-18 and overlooked Young People and Injecting Drug Use: Overcoming barriers to HIV Prevention and Harmonizing.
Glasgow Involvement Group Views from injecting drugs users in Glasgow Pathways to Treatment and Care Conference Stirling Royal Infirmary 30 th September.
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
MDM Harm Reduction (needle exchange) program in Kabul-Afghanistan.
Updating the NICE NSP Guidance Chris Carmona, Public Health Analyst Centre for Public Health.
Hepatitis C Action Plan Prevention Working Group Findings and recommendations Norah Palmateer Health Protection Scotland Greater Glasgow & Clyde MCN June.
GAP Report 2014 Prisoners People left behind: Prisoners Link with the pdf, Prisoners.
Hannah Lindsell Public Health England MEDICATIONS IN RECOVERY: RE-ORIENTATING DRUG DEPENDENCE TREATMENT HOW CAN WE MAKE SHARED-CARE IN WANDSWORTH MORE.
National AIDS Control Programme 1. National AIDS Control Programme (NACP) launched under Ministry of Health & Family Welfare in 1992 NACP I (1992 – 1999)
HIV and Hepatitis C in non- MSM Rural Communities: Issues and Interventions Shari Wells-Weiss, CASAC Director of Prevention Services Southern Tier AIDS.
Slide 5.1 Topic 5. Supporting programs aimed at reducing the spread of HIV among and from IDU Needle and Syringe Programs Opioid Substitution Treatment.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
HIV and drug prevention in Estonia Harm reduction services
Treatment of drug addiction in prisons
Module 3: HCV prevalence and course of HCV infection.
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
Louisa Degenhardt 1, Bradley Mathers 1, Peter Vickerman 2, Tim Rhodes 3, Carl Latkin 4 and Matt Hickman 5 1.National Drug and Alcohol Research Centre,
Harm Reduction.
Working with SEPs: How do we expand Hepatitis Services ? Narelle Ellendon, RN HCV Director Harm Reduction Coalition, NYC
The Policy Company Limited © Control of Infection.
Annual report 2010: the state of the drugs problem in Europe.
TI for IDUs Sexual IDUBlood Perinatal Unidentified Routes of HIV Transmission SENTINEL SURVEILLANCE 2006 HIV infection in India.
Safe Immunization Practices and Prevention of Hepatitis B and C Susan Mackay Behaviour Change Project Safe Injection Global Network.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Reaching out to drug users and communities “ ” WDP Preventing HIV Yasmin Batliwala.
NEEDLE AND SYRINGE PROGRAMMES IN THE UK Jamie Bridge, NNEF Chair
Global summary of the AIDS epidemic December 2008 Number of people living with HIV in 2008 Total 33.4 million [31.1 million–35.8 million] Adults 31.3.
Resource Needs Model Rachel Sanders October 28 th, 2010.
Module 7: Physical Health Needs Assessment. Objectives To understand the concept of harm minimisation. To be aware of the physical risks involved in drug.
National roll-out of database for HIV prevention programmes among civil society organizations in Ukraine Olga Varetska ICF “International HIV/AIDS Alliance.
Keeping up with the epidemic Programme success leaves us with new challenges: An evaluation of programmes for injecting sex workers.
Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.
Harm Reduction Team Maureen Woods Team Leader. Service Delivery Aims Develop harm reduction initiatives in partnership with other agencies to reduce the.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
Substance Misuse Treatment Framework – Needle Exchange Implications for planning and practice Carry Burton North Wales Needle Syringe Programme & Harm.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
1 NTA More treatment, better treatment, fairer treatment National injecting conference Annette Dale-Perera Director of Quality.
HIV in India David S. Hausner American Embassy School 8 th Grade Population Project 24 February 2012.
From evidence to commitment to action: implementing HIV prevention measures in prisons in Ukraine XVI International AIDS Conference Toronto, 15 August.
NPS Intravenous Use in the UK: Current Situation and Experiences Catherine Crawford, UK Focal Point.
Presented by Nathalie Rose Social Worker PILS (Prevention Information Lutte contre le Sida) 5 August, 2008 IAC.
#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.
MODULE 3 Harm reduction advocacy
Dr. Monica Beg, Chief, HIV/AIDS Section, UNODC
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Fabienne Hariga Senior Adviser, HIV/AIDS Section
6% of adults had used one or more illicit drugs in last 12 months.
Needle and syringe exchange and working with injecting drug users
Addressing Drug Use Together Through a Health Based Approach:
Jack Stone, April Young, Jennifer R. Havens, Peter Vickerman
Reitox National Focal Point National Bureau for Drug Prevention
People who inject drugs
Jonathan Mermin, MD, MPH RADM, USPHS
Coverage of HIV and HCV prevention interventions for people who inject drugs Dr Sarah Larney, Senior Research Fellow.
Global Village Debate This house would ban information dissemination on safe injecting practices, and ban the provision of clean and sterile injecting.
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
Strategies for sustainable financing of harm reduction:
Module 2: HCV transmission and risk prevention
Blood borne viral hepatitis action in Wales
Hannah Lindsell Public Health England
Human Dignity and Harm Reduction
Presentation transcript:

Meeting need and improving coverage workshop

Meeting need: calculating and improving coverage

What is coverage? Coverage is a measure of the reach of a healthcare intervention to a population Definitions have included: the range of services on offer to a geographical area % of injectors ever in contact with services % of injectors reached in a specific period number of syringes per injector per year

What is coverage? The coverage definition most appropriate for the UK is: the percentage of injections for which a new sterile syringe has been distributed by services.

why does coverage matter? Coverage matters because: we know that injectors will use a new needle and syringe if they have one evidence from Bristol showed that high coverage was associated with reduced risk of hcv infection it measures the impact of service provision on both those in contact, and those not in contact with services

The coverage calculator… As part of the Harm Reduction Works campaign we began to develop an online calculator to work out coverage. Its in a peer review process, so there will be some changes, mainly to bring it more fully into line with the NICE guidance

The calculator

what does the calculator say?

1% – 9%: coverage is very low If the figures you put in are right - there is a serious shortage of sterile injecting equipment in your area… In these conditions blood borne viruses can spread rapidly amongst injecting drug users. This coverage may be too low to prevent an HIV outbreak, and will not reduce hepatitis C (HCV) transmission. If it persists, HCV infection will rise above 50% of the injecting population, if it is not there already.

1% – 9%: advice includes ensure everyone in contact with services knows how to clean syringes with bleach so that in situations where they are reusing or sharing equipment, they can reduce the risk.

10% to 19%: coverage is low In low HIV prevalence areas (under 2%) coverage even at this level is probably high enough to prevent a widespread epidemic of HIV (but, localised epidemics are possible, and an epidemic could happen quickly if the number of infected individuals rises). in low hepatitis C prevalence areas - under 25% - coverage at this level, in conjunction with good quality opioid substitution treatment (OST), may appear to have held prevalence at its current level, however the situation could change rapidly…

10% to 19%: urgent action points Urgent action points Conduct an audit of commissioning and Needle and Syringe Programme (NSP) delivery to identify areas of non-compliance with the NICE public health guidance… Talk to injecting drug users and service providers to identify areas of low coverage and/or poor access to services and also access to syringes, sharing, and syringe reuse… Increase the number of opiate injecting drug users who have access to good quality opioid substitute prescribing;

20% – 32%: coverage needs improving If the figures you have put in - particularly the estimate for the number of injecting drug users - are right, coverage will probably prevent an HIV epidemic in low prevalence countries such as the UK. …Although it will reduce the numbers of injecting drug users catching hepatitis C, it is unlikely to make significant inroads into reducing the incidence and prevalence of hepatitis C.

20% – 32% – advice includes access to syringes is unlikely to be even… Those reliant on secondary exchange are likely to be using each syringe far more times than the average, and be more likely to share. Ensure that limits are not being placed on the amount of equipment injecting drug users can take

33% to 69%: coverage should be further improved coverage is likely to prevent an HIV epidemic while prevalence of HIV remains low. …It is also likely that there will be significant reduction in the transmission of hepatitis C. Sharing of syringes is still likely to be occurring, particularly in groups with reduced access to the injecting equipment that is being distributed.

33% to 69%: advice includes Encourage those injecting drug users in contact with services to take all the equipment they need so that they have at least one syringe for every injection, and are able to take additional equipment to distribute to their peers.

70% to 99% coverage to a substantial proportion of injectors is good, but further improvement is needed for service provision to be NICE guidance compliant

70% to 99% – advice includes Check the figures for the number of injecting drug users, the number in treatment, and number of syringes distributed are accurate, and if they are continue to: Identify high risk groups and improve access to services for them; Monitor the number of needles and syringes distributed;

100%+: coverage is excellent It is still important for services to: take steps to enable people to get into opioid substitution therapy so they can reduce or stop their injecting, and reduce the risk of accidental BBV infection and overdose